The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Uptake of maintenance immunotherapy and changes in upstream treatment selection in patients with advanced urothelial cancer (aUC).
 
Ronac Mamtani
Honoraria - Flatiron Health
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Genentech/Roche; Seattle Genetics/Astellas
Research Funding - Merck
 
Hanxi Zhang
No Relationships to Disclose
 
Ravi Bharat Parikh
Stock and Other Ownership Interests - GNS Healthcare; Google; Merck; Onc.AI
Consulting or Advisory Role - Cancer Study Group; GNS Healthcare; Humana; Merck; NanOlogy; Onc.AI; Thyme Care
Research Funding - Humana
Patents, Royalties, Other Intellectual Property - Technology to integrate patient-reported outcomes into electronic health record algorithms
Travel, Accommodations, Expenses - The Oncology Institute of Hope and Innovation
 
Aaron B. Cohen
Employment - Flatiron Health
Stock and Other Ownership Interests - Flatiron Health; Roche
 
Khilna Patel
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Blanca Homet Moreno
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Haojie Li
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kentaro Imai
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Rebecca A. Hubbard
Research Funding - Johnson & Johnson (Inst); Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA (Inst); Pfizer (Inst)